We help you join the dots...

RAS LSS is a niche strategy consultancy serving the global life sciences sector

 
 

Starting with Information Services in 2014, RAS LSS has evolved into a boutique healthcare consulting group. We offer a niche portfolio of Strategy Support and Information Services to Pharmaceutical and Medical Device Companies, throughout the product life-cycle.

We elucidate and contextualize current and future market complexities. Leveraging our collective intelligence, we strive to help our clients succeed via

  • Best In Class Situation Analysis
  • Competitively Differentiated Strategy
With an outreach across mature and emerging markets, we go the extra mile to create fresh perspectives for our clients in their mission to reduce the global burden of disease.

Check out our infographics section for latest updates!

We have put in the hours and the sweat to be credible…


Latest Blogs

May 31, 2017

Janssen @ASCO 2017

Janssen will present new data for both approved and investigational oncology compounds at ASCO 2017 Annual Meeting. 19 company-sponsored abstracts have been accepted for presentation, including for abiraterone acetate, daratumumab and ibrutinib. Most notably, Phase 3 pivotal trial results for abiraterone acetate will be featured in the ASCO Press Briefing […]
May 31, 2017

Celgene @ASCO 2017

Celgene will demonstrate its broad range of Oncology Clinical Development Program evaluating its investigational pipeline & marketed products at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 2-6 June 2017. Presentations will include multiple solid tumor and blood cancers while highlighting the value of innovative […]
May 31, 2017

Digital Health Abstracts @ ASCO 2017

The remote patient management or tele-healthcare as a concept is only starting to take off in Oncology. The readouts, though limited by their small sample size, have shown positive impact of technology on care providers, patient outcomes and the overall cost burden. Normally, larger studies would be needed to validate […]
May 30, 2017

BMS @ASCO 2017

Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program and Commitment to Exploring Novel Combinations at ASCO 2017 More than 80 presentations (including16 oral presentations and 7 poster discussions), highlighting data from Company-sponsored studies, collaborations and IS research spanning 20 types of cancer, with focus on research of precision therapies […]
May 30, 2017

AstraZeneca @ASCO 2017

AstraZeneca (AZ), along with its global biologics research and development arm, MedImmune, will demonstrate how it is rapidly delivering on the Company’s science-led strategy for transformational cancer medicine development at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 2-6 June 2017. With three new oncology […]
May 30, 2017

Amgen @ASCO 2017

Amgen announced that new clinical data and analyses from across its oncology portfolio will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2-6, 2017. Oral Presentation of New Analysis on Limited Renal Toxicity Associated With XGEVA® (denosumab) Compared With Zoledronic […]